Morgan Stanley Resumes Coverage of Covidien (COV), Baxter (BAX), Becton Dickinson (BDX), Hospira (HSP), Integra (IART)
More News related to BAX
- Baxter (BAX) to Acquire Assets of Edwards Lifesciences' (EW) Hemofiltration Product Line
- Edwards Lifesciences to Sell Its Hemofiltration Product Line to Baxter
- Baxter to Acquire Continuous Renal Replacement Therapy Business from Edwards Lifesciences
- Bank of America Starts Baxter (BAX) at Buy
- Baxter Highlights Progress Toward Sustainability Priorities in 10th Annual Sustainability Report
More News related to BDX
- BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call
- Big Brands Aim to Bolster U.S. AIDS Efforts
- BioInformatics, LLC New Report - Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations
- BD and FIND Achieve Milestone in Global Battle Against MDR-TB
- Notable Analyst Rating Changes 6/12: SKS, CSX, SNIC, PBR Upgraded; AKS, ERIC, TWTC, HGSI Downgraded
More News related to COV
- Covidien Recognized as Top Medical Devices Innovator
- Covidien Launches BariatricsPro.Com
- Covidien plc to Report Third-Quarter Results on July 30, 2009
- Covidien Features New Devices for Minimally Invasive Surgery and Soft Tissue Repair at ASMBS 2009
- Piper Jaffray initiates coverage on Covidien, Ltd. (COV) with a Neutral
After the close today, Morgan Stanley resumed coverage of several stocks in the Healthcare sector:
with an Overweight rating:
with an Underweight rating:
- Integra LifeSciences (Nasdaq: IART)
Related Categories
New CoverageStocks Mentioned
-26.44Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
